.After antibody-drug conjugate (ADC) specialist Seagen was actually sold to Pfizer in 2015 for an im...
.On the heels of a phase 3 win that neglected to make an impression on real estate investors, Ironwo...
.Don't stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after authorizing...
.Welcome to today's Chutes & Ladders, our roundup of significant management hirings, firings and ...
.Commemorating his business's upsized going public (IPO), Septerna CEO Jeffrey Finer sounded the pos...
.AbbVie has actually come back to the resource of its own antipsychotic goliath Vraylar seeking anot...
.GenSight Biologics is actually full weeks out of losing money. Once again. The biotech only possess...
.Monopar Rehabs is recuperating a medication coming from the dump of AstraZeneca's rare illness pipe...
.Along with new records out on Arcus Biosciences' speculative HIF-2a inhibitor, one group of experts...
.After creating a gene treatment collaboration along with Dyno Therapeutics in 2020, Roche is actual...
.Lundbeck is lowering the book market value of its own $250 million Abide Therapies purchase in reac...
.The assimilation of real-world data (RWD) into method feasibility as well as site option has emerge...
.At this year's Strong Biotech Peak in Boston, we caught up with innovators in the biotech business ...
.Merck & Co. is setting down $30 thousand ahead of time to purchase Yale spinout Modifi Bioscienc...
.Alpha-9 Oncology has increased a $175 thousand set C cycle to bankroll its clinical-stage radiophar...
.Eye medication creator Ocuphire Pharma is actually obtaining genetics therapy programmer Opus Genes...
.Roche's persistent cough system has actually sputtered to a standstill. The drugmaker, which axed t...
.Gilead Sciences as well as Merck & Co. have actually helped their once-weekly HIV combo therapy ...
.Lykos Rehabs may have lost three-quarters of its own workers back the FDA's turndown of its own MDM...
.Septerna might be actually as yet to divulge "any relevant clinical data," however the biotech prec...